Phase 2 trial in platinum-sensitive recurrent ovarian cancer: in 48 randomised patients, weight- and platelet-based niraparib RADAR dosing lowered grade ≥3 thrombocytopenia by cycle 3 vs standard 300 mg (4.2% vs 41.7%). Median PFS 10.3 vs 11.7 months.
RCTn = 82
Colombo et al. Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)